- cafead Jun 08, 2023 at 10:02: PM
via At a BIO panel moderated by STAT’s Torie Bosch yesterday, Amit Etkin, founder of Alto Neuroscience, argued that it’s time for a paradigm shift in how we develop drugs for mental illness. Instead of the current approach — in which people are grouped largely by symptoms — he envisions a future in which diagnoses are broken down by biomarkers. Identifying these biomarkers, and then developing drugs to target them, is increasingly possible with machine learning, he said.
article source
article source